July 13, 2022 GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood June 23, 2022 GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus June 16, 2022 GBS INC. Announces Adjournment of 2022 Annual Meeting of Stockholders to July 13, 2022 June 16, 2022 GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse May 16, 2022 GBS Inc. to Present at the H.C. Wainwright Global Investment Conference May 13, 2022 GBS Inc. to Hold Virtual 2022 Annual Shareholder Meeting on Thursday, June 16, 2022, at 4:00pm ET May 10, 2022 GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights May 3, 2022 GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10 March 31, 2022 GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center March 7, 2022 GBS Inc. to Participate in the Upcoming March Investor Conferences
July 13, 2022 GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood
June 16, 2022 GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse
May 13, 2022 GBS Inc. to Hold Virtual 2022 Annual Shareholder Meeting on Thursday, June 16, 2022, at 4:00pm ET
May 3, 2022 GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10
March 31, 2022 GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center
